Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Oryctolagus cuniculus | Arachidonate 15-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Arachidonate 15-lipoxygenase | 663 aa | 676 aa | 22.5 % |
Echinococcus granulosus | arachidonate 5 lipoxygenase | Arachidonate 15-lipoxygenase | 663 aa | 676 aa | 23.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | cathepsin B-like cysteine proteinase | 0.2805 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VII | 0.0354 | 0 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.2805 | 0.2898 | 0.2898 |
Onchocerca volvulus | 0.0354 | 0 | 0.5 | |
Toxoplasma gondii | cathepsin B | 0.0926 | 0.0676 | 1 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.2805 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VI | 0.0354 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin X | 0.0354 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.0354 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0354 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IX | 0.0354 | 0 | 0.5 |
Trypanosoma brucei | cysteine peptidase C (CPC) | 0.0926 | 0.0676 | 0.5 |
Loa Loa (eye worm) | cathepsin B | 0.0926 | 0.0676 | 0.2333 |
Echinococcus multilocularis | cathepsin b | 0.2805 | 0.2898 | 1 |
Onchocerca volvulus | 0.0354 | 0 | 0.5 | |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0926 | 0.0676 | 0.0676 |
Plasmodium falciparum | plasmepsin IV | 0.0354 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0354 | 0 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.2805 | 0.2898 | 0.2898 |
Echinococcus granulosus | cathepsin b | 0.2805 | 0.2898 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2805 | 0.2898 | 1 |
Echinococcus granulosus | cathepsin b | 0.2805 | 0.2898 | 1 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0926 | 0.0676 | 1 |
Plasmodium vivax | aspartyl protease, putative | 0.0354 | 0 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0926 | 0.0676 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0926 | 0.0676 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0926 | 0.0676 | 0.5 |
Plasmodium falciparum | plasmepsin V | 0.0354 | 0 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.2805 | 0.2898 | 0.2898 |
Plasmodium vivax | plasmepsin V, putative | 0.0354 | 0 | 0.5 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.2805 | 0.2898 | 0.2898 |
Plasmodium falciparum | plasmepsin II | 0.0354 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin VIII, putative | 0.0354 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.2805 | 0.2898 | 1 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0354 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0354 | 0 | 0.5 |
Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.0926 | 0.0676 | 0.5 |
Plasmodium falciparum | plasmepsin III | 0.0354 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0354 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.082 uM | Inhibition of rabbit 15-lipoxygenase in presence of linoleic acid | ChEMBL. | 17656086 |
IC50 (binding) | = 0.082 uM | Inhibition of rabbit 15-lipoxygenase in presence of linoleic acid | ChEMBL. | 17656086 |
IC50 (binding) | = 0.531 uM | Inhibition of rabbit 15-lipoxygenase in presence of arachidonic acid | ChEMBL. | 17656086 |
IC50 (binding) | = 0.531 uM | Inhibition of rabbit 15-lipoxygenase in presence of arachidonic acid | ChEMBL. | 17656086 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.